Cambridge Consultants and Sun Pharma Advanced Study Organization Ltd develop a high efficiency, simple to use dry powder inhaler

Cambridge Consultants, a leading technology item style and development firm, has created a new high efficiency, effortless to use dry powder inhaler in collaboration with Sun Pharma Advanced Study Firm Ltd (“SPARC”), 1 of India’s leading pharmaceutical study businesses. The inhaler has a uniform delivery profile that ensures the full intended metered dose of the drug is administered to the deep lung, regardless of the strength of the patient’s intake of breath.

The device employs a novel de-agglomeration engine to separate the drug from the lactose ‘carrier’ particles. Based on a highly efficient airway style, the patented drug separation mechanism has effectively completed clinical trials and demonstrated that it is capable of delivering significantly more of the drug to the deep lung than conventional inhalers. In practice, this will minimise side effects from drug develop-up in the back of the throat, reduce non-systemic load and wastage, and means almost 50% much less active drug requirements pre-loading into the device in comparison to a standard inhaler.

This step alter in inhaler technologies is a dependable and straightforward to use device, particularly for patients with impaired lung function or those employing the inhaler during an asthma attack – overcoming any patient concerns about the capacity to use the device efficiently.

In addition to its novel drug delivery mechanism, the device integrates a number of user-friendly style features. These incorporate a numerical dose counter to indicate at a glance how several more doses are left in the inhaler ahead of it runs out, a luminous feature to allow users to uncover the device in the dark and a tiny pop-out ‘braille’ button which activates when there are only a few doses remaining. The device provides audible and tactile feedback to indicate the delivery and completion of user steps. The device also features a exclusive palm-held form, designed to discreetly house the complicated dose carriage and delivery method however stay comfortable to hold and use.

Mr Dilip S. Shanghvi, Chairman and Managing Director of SPARC, commented, “Our search for the right design expertise for this project was global, but Cambridge Consultants stood out to us because of its outstanding track record in medical device development. The partnership has worked extremely nicely and has enabled us to take the item from initial requirement to market in half the time that such projects typically demand.”

Phil Lever, Commercial Director at Cambridge Consultants, added, “We’re delighted that SPARC chose to function with us on the technically difficult project as we really feel this is a strong endorsement of the world-class development abilities we offer, and we are extremely proud of the inhaler that has been developed as a result of this collaborative partnership.” Cambridge Consultants and SPARC are now working together to prepared the device for manufacture and the commercial launch is expected in 2011.

Cambridge Consultants will also be demonstrating the device at the Drug Delivery to the Lungs (DDL) 21 conference, Edinburgh International Conference Centre, 8th-10th December 2010.

Notes for editors:

Cambridge Consultants develops breakthrough items, creates and licenses intellectual property, and offers company consultancy in technologies critical issues for clients worldwide. For 50 years, the organization has been helping its customers turn organization opportunities into commercial successes, no matter whether they are launching first-to-marketplace goods, entering new markets or expanding existing markets by way of the introduction of new technologies. With a team of more than 300 engineers, designers, scientists and consultants, in offices in Cambridge (UK) and Boston (USA), Cambridge Consultants provides solutions across a diverse range of industries such as medical technology, industrial and consumer goods, transport, power, cleantech and wireless communications.

All through 2010, Cambridge Consultants celebrates its 50th year in business. Designed by three Cambridge graduates in 1960, the firm has grown into a leading technologies organization, renowned worldwide for its capability to solve technical issues and offer innovative, practical solutions to commercial problems. In 2009, the firm was awarded the prestigious Queen’s Award for Enterprise in International Trade. For more data visit: www.CambridgeConsultants.com

Cambridge Consultants is component of Altran, the European leader in innovation and high technologies consulting. The Group’s 17,500 consultants, operating worldwide, cover the whole range of engineering specialities, such as electronics, info technology, high quality and organisation. Altran delivers its clients ongoing support all through the innovation cycle, from technology watch, applied fundamental study and management consulting to industrial systems engineering and details systems. The Group offers services to most industries, including the automotive, aeronautics, space, life sciences and telecommunications sectors. Founded in 1982, Altran operates in 20 priority countries. In 2008, it generated a turnover of €1,650 million. For a lot more details visit: www.altran.com

About SPARC

Sun Pharma Advanced Research Firm Ltd (NSE: SPARC, BSE: 532872) is an international pharmaceutical company engaged in investigation and development of drugs and delivery systems. Far more information about the organization can be identified at www.sunpharma.in.

source